LXRβ agonists (GW3965, RGX-104a)Induction of MDSC apoptosis and improved anti-tumor response (pre-clinical) in combination with checkpoint blockade.RGX-104 is in clinical trial for solid tumors as a single agent and in combination with PD-1 inhibitor (NCT02922764). The gene discussed is NR1H2; the disease is neoplasm.